YU87990A - Postupak za dobijanje novih bis-(1h-indol-3-il)-maleinimid derivata - Google Patents

Postupak za dobijanje novih bis-(1h-indol-3-il)-maleinimid derivata

Info

Publication number
YU87990A
YU87990A YU87990A YU87990A YU87990A YU 87990 A YU87990 A YU 87990A YU 87990 A YU87990 A YU 87990A YU 87990 A YU87990 A YU 87990A YU 87990 A YU87990 A YU 87990A
Authority
YU
Yugoslavia
Prior art keywords
indol
preparation
derivatives
maleinimid
new bis
Prior art date
Application number
YU87990A
Other languages
English (en)
Inventor
Hubert Barth
Johannes Hartenstein
Claus Rudolph
Christoph Schaechtele
Hans-Jurgen Betche
Hartmut Oswald
Reinhard Reck
Original Assignee
Goedecke Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3914764A external-priority patent/DE3914764A1/de
Priority claimed from DE19893942991 external-priority patent/DE3942991A1/de
Application filed by Goedecke Ag. filed Critical Goedecke Ag.
Publication of YU87990A publication Critical patent/YU87990A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Image Processing (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Aerodynamic Tests, Hydrodynamic Tests, Wind Tunnels, And Water Tanks (AREA)

Abstract

POSTUPAK ZA DOBIJANJE NOVIH BIS-(1H-INDOL-3-IL)-MALEINIMID DERIVATA. Opisani su bis-(1H-indol-3-il)-maleinimidni derivati formule (I) u kojoj R1 i/ili R2 predstavljaju vodonik, metil, etil i n-propil, R3, R6, R7 i R10 vodonik, R4, R5, R8 i R9 nezavisno predstavljaju vodonik ili halogen i njihove farmakološki prihvatljive soli, postupci za dobijanje tih jedinjenja i farmaceutski preparati koji ih sadrže za tretiranje srčanih oboljenja i bolesti krvnih sudova, kao što je tromboza, arterioskleroza, hipertenzija, za tretiranje inflamatornih procesa, alergije, kancera i odredjenih degenerativnih oštećenja centralnog nervnog sistema, kao i bolesti imunog sistema i virusnih bolesti.
YU87990A 1989-05-05 1990-05-04 Postupak za dobijanje novih bis-(1h-indol-3-il)-maleinimid derivata YU87990A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3914764A DE3914764A1 (de) 1989-05-05 1989-05-05 Maleinimid-derivate und deren verwendung als arzneimittel
DE19893942991 DE3942991A1 (de) 1989-12-27 1989-12-27 Maleinimid-derivate und deren verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
YU87990A true YU87990A (sh) 1992-07-20

Family

ID=25880591

Family Applications (1)

Application Number Title Priority Date Filing Date
YU87990A YU87990A (sh) 1989-05-05 1990-05-04 Postupak za dobijanje novih bis-(1h-indol-3-il)-maleinimid derivata

Country Status (16)

Country Link
EP (1) EP0397060B1 (sh)
JP (1) JP2983248B2 (sh)
KR (1) KR900018080A (sh)
AT (1) ATE209202T1 (sh)
AU (1) AU634541B2 (sh)
CA (1) CA2015996C (sh)
DE (1) DE59010927D1 (sh)
DK (1) DK0397060T3 (sh)
ES (1) ES2169719T3 (sh)
FI (1) FI902251A0 (sh)
HU (1) HU207727B (sh)
IL (1) IL94274A0 (sh)
NO (1) NO179748C (sh)
NZ (1) NZ233560A (sh)
PT (1) PT93947B (sh)
YU (1) YU87990A (sh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
EP0630241A1 (en) * 1992-03-20 1994-12-28 The Wellcome Foundation Limited Indole derivatives with antiviral activity
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
HUT69164A (en) * 1993-12-07 1995-08-28 Lilly Co Eli Improved process for producing bis-indolyl-maleimide derivatives
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
AU687909B2 (en) * 1993-12-07 1998-03-05 Eli Lilly And Company Protein kinase C inhibitors
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
CN1106400C (zh) * 1994-05-09 2003-04-23 万有制药株式会社 抗肿瘤吲哚并吡咯并咔唑衍生物
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
JP4100708B2 (ja) * 1995-11-20 2008-06-11 イーライ リリー アンド カンパニー Ｎ，ｎ’−架橋ビスインドリルマレイミドの製造における新規中間体およびその用途
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91498A1 (es) * 1996-07-29 1998-12-22 Hoffmann La Roche Pirroles sustituidos
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
DE69727305T2 (de) * 1996-10-31 2004-06-24 Harbor Branch Oceanographic Institution, Inc., Fort Pierce Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
EP1057484A4 (en) * 1998-02-23 2002-11-20 Sagami Chem Res INHIBITORS OF CELL DEATH
WO2000002857A1 (en) 1998-07-08 2000-01-20 Harbor Branch Oceanographic Institution, Inc. Bis-indole derivatives and their use as antiinflammatory agents
EP1152002A4 (en) * 1999-02-09 2002-04-17 Sagami Chem Res PYRROL DERIVATIVES AND CELL DEATH INHIBITORS
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
DK1441737T3 (da) 2001-10-30 2006-11-13 Novartis Ag Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
JPWO2004091663A1 (ja) * 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
NZ560225A (en) 2005-02-09 2010-10-29 Arqule Inc Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
CA2912546A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Compositions and methods for treatment of cancer
US8232285B2 (en) 2007-06-22 2012-07-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
US8193235B2 (en) * 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders

Also Published As

Publication number Publication date
JP2983248B2 (ja) 1999-11-29
DE59010927D1 (de) 2002-01-03
PT93947B (pt) 1996-11-29
EP0397060B1 (de) 2001-11-21
AU634541B2 (en) 1993-02-25
DK0397060T3 (da) 2002-05-21
NO901989L (no) 1990-11-06
NZ233560A (en) 1992-01-29
HU902681D0 (en) 1990-09-28
CA2015996A1 (en) 1990-11-05
CA2015996C (en) 2001-08-28
ATE209202T1 (de) 2001-12-15
NO179748B (no) 1996-09-02
EP0397060A3 (de) 1992-01-02
NO901989D0 (no) 1990-05-04
EP0397060A2 (de) 1990-11-14
FI902251A0 (fi) 1990-05-04
NO179748C (no) 1996-12-11
HUT53902A (en) 1990-12-28
JPH02306974A (ja) 1990-12-20
ES2169719T3 (es) 2002-07-16
AU5466690A (en) 1990-11-08
PT93947A (pt) 1991-01-08
KR900018080A (ko) 1990-12-20
IL94274A0 (en) 1991-03-10
HU207727B (en) 1993-05-28

Similar Documents

Publication Publication Date Title
YU87990A (sh) Postupak za dobijanje novih bis-(1h-indol-3-il)-maleinimid derivata
FI904204A0 (fi) Foerfarande foer framstaellning av cykliska aminosyraderivat och mellanprodukter.
NO944564L (no) Indolcarbazol-imider og deres anvendelse
NO910444D0 (no) Alkoksy-4(1h)-pyridonderivater, fremgangsmaater for fremstilling derav og deres anvendelse som legemiddel.
GR3020866T3 (en) Indolocarbazole derivatives, processes for their preparation and their use
NO178661C (no) Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoksalinforbindelser
FI884553A0 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 9-aminotetrahydroakridiinijohdannaisten valmistamiseksi
GR3003452T3 (en) Indolocarbazole derivatives, processes for their preparation and their use as medicaments
HUT34478A (en) Process for producing hexahydro-pyrrolo/2.1-a/isoquinoline derivatives and pharmaceutical compositions containing them
DE58906571D1 (de) 2-Aminocarbonsäuren und deren Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel.